TNF and infection: Since prolonged anti TNF-α or IL-17 therapies bear the risk of severe infections or development of metaplastic malignancies (28, 34, 35), only short-term treatment with combined anti-IL-17/anti-TNF-α antibodies might be qualified for the treatment of infection-triggered exacerbation of AAI.